GV participated as a new investor, as Harvard's genetic medicine developer Beam Therapeutics completed a round that followed $87m in series A funding last year.

Beam Therapeutics, a US-based genetic medicine spinout of Harvard University, closed a $135m series B round yesterday that included GV, the subsidiary of internet and technology group Alphabet formerly known as Google Ventures. F-Prime Capital and Eight Roads Ventures, subsidiaries of investment and financial services group Fidelity, also took part in the round, as did…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.